THE β-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-1 strains of the non-syncytium-inducing (NSI) phenotype with CD4+ T-cells1–5. The primary binding site for human immunodeficiency virus (HIV)-1 is the CD4 molecule, and the interaction is mediated by the viral surface glycoprotein gp120 (refs 6, 7). The mechanism of CCR-5 function during HIV-1 entry has not been defined, but we have shown previously that its β-chemokine ligands prevent HIV-1 from fusing with the cell1. We therefore investigated whether CCR-5 acts as a second binding site for HIV-1 simultaneously with or subsequent to the interaction between gp120 and CD4. We used a competition assay based on gp120 inhibition of the binding of the CCR-5 ligand, macrophage inflammatory protein (MIP)-1β, to its receptor on activated CD4+ T cells or CCR-5-positive CD4− cells. We conclude that CD4 binding, although not absolutely necessary for the gp120–CCR-5 interaction, greatly increases its efficiency. Neutralizing monoclonal antibodies against several sites on gp120, including the V3 loop and CD4-induced epitopes, inhibited the interaction of gp120 with CCR-5, without affecting gp120–CD4 binding. Interference with HIV-1 binding to one or both of its receptors (CD4 and CCR-5) may be an important mechanism of virus neutralization.
Subscribe to Journal
Get full journal access for 1 year
only $3.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dragic, T. et al. Nature 381, 667–673 (1996).
Deng, H. K. et al. Nature 381, 661–666 (1996).
Choe, H. et al. Cell 86, 1135–1148 (1996).
Doranz, B. J. et al. Cell 86, 1149–1159 (1996).
Alkhatib, G. et al. Science 272, 1955–1958 (1996).
Maddon, P. J. et al. Cell 47, 333–348 (1986).
Lasky, L A. et al. Cell 50, 975–985 (1987).
Wells, T. N. C. et al. J. Leuk. Biol. 59, 53–60 (1996).
Samson, M., Labbe, O., Mollereau, C., Vassart, G. & Parmentier, M. Biochemistry 11, 3362–3367 (1996).
Raport, C. J., Gosling, J., Schweickart, V. L., Gray, P. W. & Charo, I. F. J. Biol. Chem. 271, 17161–17166 (1996).
Neote, K., DiGregorio, D., Mak, J. Y., Horuk, R. & Schall, T. J. Cell 72, 415–425 (1993).
Loetscher, P., Seitz, M., Baggiolini, M. & Moser, B. J. Exp. Med. 184, 569–578 (1996).
Paxton, W. A. et al. Nature Med. 2, 412–417 (1996).
Liu, R. et al. Cell 86, 367–378 (1996).
Weissenhorn, W. et al. EMBO J. 15, 1507–1514 (1996).
Healey, D. et al. J. Exp. Med. 172, 1233–1242 (1990).
Allaway, G. P. et al. AIDS Res. Hum. Retrovirus 11, 533–540 (1995).
Moore, J. P. & Ho, D. D. AIDS 9 (suppl. A), S117–S136 (1995).
Moore, J. P., Sattentau, Q. J., Wyatt, R. & Sodroski, J. J. Virol. 68, 469–484 (1994).
Moore, J. P. & Sodroski, J. J. Virol. 70, 1863–1872 (1996).
Cheng-Mayer, C. AIDS 4 (suppl. 1), S49–S56 (1990).
Thali, M. et al. J. Virol. 67, 3978–3988 (1993).
Wyatt, R. et al. J. Virol. 69, 5723–5733 (1995).
Moore, J. P., Yoshiyama, H., Ho, D. D., Robinson, J. E. & Sodroski, J. AIDS Res. Hum. Retroviruses 9, 1179–1187 (1993).
Sullivan, N., Sun, Y., Li, J., Hoffmann, W. & Sodrski, J. J. Virol. 69, 4413–4422 (1995).
Allan, J. S., Strauss, J. & Buck, D. W. Science 247, 1084–1088 (1990).
Burkly, L. C. et al. J. Immunol. 149, 1779–1787 (1992).
Gorny, M. K. et al. J. Virol. 68, 8312–8320 (1994).
White-Scharf, M. E. et al. Virology 192, 197–208 (1993).
Lu, S. et al. J. Virol. 70, 3978–3991 (1996).
About this article
Cite this article
Trkola, A., Dragic, T., Arthos, J. et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384, 184–187 (1996). https://doi.org/10.1038/384184a0
Characterizing the Latent HIV-1 Reservoir in Patients with Viremia Suppressed on cART: Progress, Challenges, and Opportunities
Current HIV Research (2020)
Biochimica et Biophysica Acta (BBA) - Biomembranes (2020)
Communications Biology (2020)
PLOS Pathogens (2020)
Journal of Virology (2020)